Scenic Biotech

Scenic Biotech is a biotechnology company founded in 2017 as a spin-out of the Netherlands Cancer Institute and Oxford University. The company is pioneering 'modifier therapy,' a novel approach to treating genetic disorders by targeting genetic modifiers—genes that naturally suppress or counteract the effects of disease-causing mutations. This approach differs fundamentally from conventional therapeutics by rebalancing health through secondary genome functions rather than directly targeting primary mutations. Scenic's proprietary Cell-Seq platform enables the systematic discovery of disease-modifying genes and has generated an extensive data warehouse of genetic modifiers. The company is advancing a robust pipeline of first-in-class small molecule programs across immuno-oncology and rare genetic diseases, with strategic collaborations with major pharmaceutical partners including Genentech (Roche), Bristol Myers Squibb, and Alnylam.